References
Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D (2012) Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma 53:1625–1626
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH (2015) Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 372:1430–1440
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C, iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia (2018) Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med 378:2399–2410
Patel K, Saliba RM, Shah N, Bashir Q, Thomas SK, Dinh YT et al (2012) Autologous stem cell transplantation in Waldenstrom’s macroglobulinemia. Blood 120. http://www.bloodjournal.org/content/120/21/4533?sso-checked=true. Accessed 17 Sep 2018
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G (2009) International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113:4163–4170
Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrák K, Corradini P, Sureda A, Schmitz N (2010) High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28:2227–2232
Marzolini MAV, Thomson KJ, Dorman J, D’Sa S (2014) BEAM-conditioned autologous SCT improves the quality of response in Waldenström’s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre’s 10-year experience. Bone Marrow Transplant 49:1231–1232
Caravita T, Siniscalchi A, Tendas A, Cupelli L, Dentamaro T, Natale G, Spagnoli A, de Fabritiis P (2009) High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom’s macroglobulinemia. Bone Marrow Transplant 43:587–588
Baron M, Simon L, Poulain S, Leblond V (2019) How recent advances in biology of Waldenström’s macroglobulinemia may affect therapy strategy. Curr Oncol Rep 21:27
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors do not have any relevant conflict of interest to declare.
Ethical approval
This was a retrospective evaluation of patient’s chart data and approval was obtained from the Institutional Research Board at MD Anderson Cancer Center. The study was conducted in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Saini, N.Y., Patel, R.D., Varma, A. et al. Outcomes of autologous stem cell transplantation in Waldenström’s macroglobulinemia. Ann Hematol 98, 2233–2235 (2019). https://doi.org/10.1007/s00277-019-03734-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-019-03734-7